F-1/A: Phaos Technology Files Amended F-1 for Share Offering

Phaos Technology Holdings (Cayman) Limited has filed an amended F-1 registration statement detailing its offering of Class A Ordinary Shares and Warrants, alongside its financial performance and business outlook.

Summary

• Phaos Technology Holdings (Cayman) Limited has filed an amended F-1 registration statement for an offering of Class A Ordinary Shares and Warrants.
• The company, which assembles and commercializes advanced microscopy solutions, reported a significant revenue decline for the year ended April 30, 2025, to S$167,707 from S$1,882,803 in the prior year, primarily due to reduced sales from major customers.
• Despite the revenue drop, the company has focused on customer diversification and cost management, reducing its workforce and monthly operating expenses.
• For the six-month period ended October 31, 2025, revenue increased by 38.8% to S$87,617, and net loss decreased by 25.4% to S$1,505,248.
• The company highlights its patented microsphere-assisted technology, enabling imaging below the optical diffraction limit, and its integrated AI-powered software solutions.
• Phaos Technology is addressing substantial doubt about its ability to continue as a going concern through a capital raising strategy.
• The filing includes details on the company's dual-class share structure, risks associated with its business, and its market position in Asia.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline, substantial net losses, and going concern uncertainties, despite some recent operational improvements and a planned capital raise.

Positives

• Revenue increased by 38.8% to S$87,617 for the six-month period ended October 31, 2025, compared to the prior year.
• Net loss decreased by 25.4% to S$1,505,248 for the six-month period ended October 31, 2025.
• Gross margin improved to 41.8% for the six-month period ended October 31, 2025, from 12.7% in the prior year.
• The company has reduced its workforce and monthly operating expenses to below S$200,000.
• Phaos Technology possesses patented microsphere-assisted technology for super-resolution imaging.
• The company has integrated proprietary AI software into its microscopy hardware, creating a synergistic ecosystem.
• The company has obtained ISO 9001/14001/45001 certifications, demonstrating commitment to quality management.

Negatives

• Revenue for the year ended April 30, 2025, decreased by 91.1% to S$167,707 from S$1,882,803 in the prior year.
• The company has incurred significant net losses, with a net loss of S$5,137,064 for the year ended April 30, 2025.
• There is substantial doubt about the company's ability to continue as a going concern.
• Customer concentration remains high, with the top five customers accounting for 85% of revenue for the year ended April 30, 2025.
• The company has a limited cash balance of S$54,989 as of October 31, 2025.
• The company has provided a loan to PT Neura Integrasi Solusi, which has been partially impaired, posing a risk of non-recovery.
• The company's dual-class share structure may discourage change of control transactions and affect the liquidity of Class A shares.

Risks

• The company is an early revenue stage company with a history of operating losses and does not know when it will attain profitability.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has significant customer concentration, with top customers accounting for a large portion of revenue.
• The company's expansion of direct sales efforts may not be successful and could adversely affect its business.
• The market price of Class A Ordinary Shares has been and may continue to be highly volatile.
• The company may not be able to maintain its listing on NYSE American, which could limit investors' ability to trade its shares.
• The company faces risks related to supply chain interruptions and fluctuations in material prices.
• The company is subject to risks arising from fluctuations in foreign currency exchange rates.

Future Outlook

The company aims to strengthen its market position through regional expansion, digital marketing, and widening its product range, including new developments in digital pathology and Optical Coherence Tomography. However, it faces challenges related to customer concentration, liquidity, and the need for additional capital.

Management Comments

• Management believes that the workforce reduction has not adversely affected the Company's ability to support its existing operations, attract or retain personnel, or continue implementing its direct sales strategy.
• Management expects that ongoing customer diversification and regional expansion efforts will allow for increased and stabilized product sales over time.
• Management expects that certain IPO-related costs will not recur in future periods, although the Company will continue to incur ongoing public company compliance costs.

Industry Context

StockSavvy.ai notes that Phaos Technology operates in the competitive microscopy equipment market, facing established players like Keyence, Nikon, and Olympus. The company's strategy to differentiate through patented technology and integrated AI software aims to capture market share in specialized applications.

Management Changes

Corporate Governance

Related Party Transactions

• The Company has received significant financial support from its major shareholder, Tonghuai SG Enterprise Pte. Ltd., in the form of interest-free, unsecured loans totaling S$3,755,423 as of October 31, 2025.

Stakeholder Impact

• Shareholders face risks of substantial losses due to stock price volatility and potential dilution from future financings.
• Employees were reduced from 25 to 10 full-time employees to align costs with operational needs.
• Customers may experience disruptions if equipment failures occur, potentially impacting the company's reputation and profitability.

Next Steps

• Complete the initial public offering (IPO) of Class A Ordinary Shares and Warrants.
• Utilize proceeds from the offering for expansion of supply chain, marketing and promotion, and working capital.
• Continue efforts to diversify customer base and expand into Southeast Asian markets.
• Develop new product series for biomedical applications and explore collaborations for new technologies.
• Continue to implement direct sales strategy and enhance after-sales service capabilities.

Key Dates

Recommendation

The company exhibits significant financial distress, including a sharp revenue decline, substantial net losses, and a going concern warning. While there are efforts to diversify and manage costs, the high customer concentration and volatile stock performance present considerable risks. The planned offering and potential capital raises are necessary for survival but do not negate the fundamental business challenges.

Keywords

microscopy solutions, super-resolution imaging, AI microscopy, biomedical imaging, industrial inspection, SEC filing, F-1 registration, Phaos Technology